The phrase that started it
It started with a creatine review. One of our researchers wrote that a product was "clinically dosed at 5g." Someone pushed back: clinically dosed according to which trial? The loading-protocol studies used 20g/day for five days. The maintenance studies used 3–5g. A handful of cognitive studies used 20g acutely. Which one counts?
The argument went in circles for two weeks. Then it came up again with ashwagandha — KSM-66 trials have used anywhere from 240mg to 600mg, with the most-cited stress RCTs landing at 300–600mg. Then magnesium, where the glycinate studies range from 200mg to 400mg elemental depending on the endpoint being measured. Then vitamin D, where the therapeutic correction literature lives in a completely different dose universe from the maintenance literature.
We kept writing "clinically dosed" in our reviews as if it meant something precise. We owed it to our readers — and to ourselves — to nail down what we actually meant.
"Clinically dosed" is one of the most useful phrases in supplement writing and one of the most abused. The two are related.
What the industry means by it
When a supplement brand uses "clinically dosed," they typically mean one or more of the following — and it's worth being clear about which claim is being made:
- The dose matches a cited study. The weakest version. Any study, any population, any endpoint. A single 2003 in vitro paper using ashwagandha extract on rat cells technically "clinically" validates any dose that happens to match.
- The dose matches the most commonly studied range. Better. Still requires knowing what the distribution of trial doses actually looks like, which most people don't.
- The dose matches the dose that showed a statistically significant effect in the best available trial. This is the standard we actually want — and it's the one that's almost never specified.
The industry has no formal definition. "Clinically dosed" is not a regulated term under FSSAI in India, not under FDA in the US, not under EFSA in Europe. Any brand can print it on any product at any dose. It costs nothing.
The most aggressive version of fake clinical dosing: list several ingredients with strong evidence on the label, cite the RCTs for each, and then hide all of them inside a proprietary blend that weighs less than the single effective dose of any one ingredient. The brand can truthfully claim every ingredient is "studied" — while every ingredient is below the studied dose. This is standard practice in Indian pre-workout and fat-burner categories.
The actual internal argument
Our team split into two rough positions. Neither is entirely wrong. That's what makes it a real argument rather than a mistake.
"Clinical dose" should mean the dose from the highest-quality trial that showed the primary effect."
A dose is only "clinical" if it maps directly to a specific study outcome in a specific population. You should name the trial. If the creatine evidence comes from Kreider et al., say so and say what dose they used. Generic "5g is clinical" collapses the complexity of a literature that actually spans 2–20g across different endpoints and populations. Readers deserve the specific citation, not the abstracted claim.
"Clinical dose" can reasonably mean the consensus effective range across the body of evidence."
Individual trials vary in design, population, and endpoint. Pinning a single dose to a single trial is too brittle — a subsequent meta-analysis might shift the consensus. "Clinically dosed" used to describe a dose that sits within the range consistently used in well-designed RCTs is accurate and useful, as long as that range is disclosed. Demanding one specific trial per claim sets an editorial standard that no publication meets.
Position B is practically correct but epistemically lazy if used as a blanket justification for vague language. Position A is epistemically correct but breaks down when the literature genuinely has no single canonical trial — which is true for most supplements.
The resolution we're implementing: "clinically dosed" in NC reviews now always comes with a parenthetical that specifies the evidence basis — either a named trial, a named meta-analysis, or an explicit range statement citing at least two trials. "Clinically dosed (3–5g/day, Kreider et al. 2017 consensus position; Rawson & Volek 2003)" is acceptable. "Clinically dosed" alone, without that parenthetical, is not.
The problems that didn't get resolved
The parenthetical rule handles the clearest cases. It doesn't handle three situations that kept coming up and remain genuinely contested on the team.
Problem 1: Population mismatch
The vast majority of supplement RCTs were conducted on Western populations — young, male, resistance-training athletes in American or European university labs. When we call a creatine dose "clinical" for a 45-year-old sedentary vegetarian woman in Hyderabad, we're extrapolating beyond the evidence base.
Body weight matters for creatine (the commonly cited 0.1g/kg/day loading dose means a 55kg Indian woman needs 5.5g, not 20g). Dietary background matters for omega-3 (baseline omega-6:omega-3 ratios in Indians consuming mustard oil or sunflower oil are far higher than in Western trial populations, which may affect the effective dose required for a given anti-inflammatory endpoint). (observational)
We don't have a clean answer here. The literature we're citing was not built for Indian bodies, Indian diets, or Indian deficiency profiles. The clinical dose we're reporting is the dose that worked in a population that is not our readership. We flag this where we can; we can't always quantify how much it matters.
Problem 2: Maintenance vs. correction vs. therapeutic
This is the one Sumita raised most forcefully during review, and it's particularly acute in the vitamins and minerals category she covers. Take vitamin D:
| Context | Dose used in trials | "Clinical dose" claim | Honest label? |
|---|---|---|---|
| Deficiency correction (25-OHD < 20 ng/mL) | 60,000 IU/week bolus (Indian protocols); 4,000–6,000 IU/day × 8–12 wks (Western) | "Clinically effective for deficiency correction" | Accurate in context |
| Maintenance (25-OHD ≥ 40 ng/mL) | 1,000–2,000 IU/day (Endocrine Society guideline) | "Clinically dosed at 2,000 IU" | Accurate in context |
| Both lumped together on one product label | Product says "2,000 IU — clinically dosed for vitamin D support" | "Clinically dosed" | Conflation — correction and maintenance are different clinical problems |
The same product can be correctly dosed for one clinical problem and inadequately dosed for another. A 2,000 IU/day supplement is fine for a person who is already replete; it will do almost nothing for someone with a 25-OHD of 12 ng/mL who needs supervised correction first. When a label says "clinically dosed" without specifying which clinical problem is being solved, it is — technically — not lying. But it is misleading by omission.
Our working rule, still contested: NC reviews now specify the clinical context, not just the dose. "2,000 IU — appropriate for maintenance dosing in replete adults; insufficient for correction of deficiency without medical supervision."
Problem 3: The single-ingredient vs. stack problem
This is where we genuinely haven't reached consensus yet.
Many RCTs that established effective doses used the ingredient in isolation. But products are rarely single-ingredient. When you combine caffeine (200mg) with L-theanine (200mg), the evidence for the combination specifically is different — and arguably better — than either alone. (RCT) The 1:1 ratio has RCT support specifically as a combination; you can't simply add the individual evidence bases together.
In the opposite direction: some ingredients have lower effective doses in combination because they potentiate each other. Ashwagandha with black pepper (piperine) is a standard example — piperine inhibits CYP3A4 and slows metabolism of certain compounds, potentially allowing a lower dose to maintain serum levels longer. Whether that changes the "clinical dose" of ashwagandha in combination is a question the literature doesn't answer cleanly. (in vitro; limited RCT)
For multi-ingredient products, we currently score each ingredient against its single-ingredient evidence base, flag the combination where combination-specific evidence exists, and note when the combination is likely to affect dose requirements in either direction. It's the least-wrong approach we've found. It's not fully satisfying.
Why this is specifically an India problem
Indian supplement marketing has imported the "clinically dosed" language from American sports nutrition culture — where it emerged as a reaction against proprietary blends — without importing the evidentiary standards that were supposed to come with it.
Walk into any GNC, HealthKart, or supplement-heavy pharmacy in Bengaluru, Mumbai, or Gurugram. Count the products that say "clinically dosed" or "scientifically validated" on the front panel. Now open the label. Count how many tell you which trial, at what dose, in what population. The number is close to zero.
Under the Food Safety and Standards (Labelling and Display) Regulations, 2020, supplement labels in India cannot make disease-treatment claims — but "clinically dosed" is not a disease claim. It is a characterisation of the dose, and it remains entirely unregulated. FSSAI's Schedule K sets permitted ingredient lists and maximum dosages, but it says nothing about whether a brand can claim its dose is "clinical." The phrase is marketing, not a regulatory standard.
This matters because Indian consumers are increasingly supplement-literate and actively looking for the signal that a product isn't placebo-priced pixie dust. "Clinically dosed" has become that signal — which means brands have every incentive to print it regardless of whether it's meaningful, and consumers have little ability to verify it without reading primary literature.
Our reviews are an attempt to close that gap. But we're also aware that every time we use the phrase imprecisely, we contribute to the noise we're trying to reduce.
What we're doing about it
As of the May 2026 methodology update, here is the internal standard NC reviewers are required to follow when making dosing claims:
1. Name the evidence basis. Every dose claim links to a specific named trial, meta-analysis, or guideline statement. "5g/day (Kreider et al. 2017 ISSN position stand)" not "5g/day (clinical dose)."
2. Specify the clinical context. Correction, maintenance, and therapeutic are distinct. Label them.
3. Flag population mismatch. If the trial population differs materially from the Indian supplement buyer — age, sex, training status, dietary pattern, baseline deficiency status — note it.
4. Score underdosing as a Dose dimension deduction, not just a note. A product at 60% of the lowest effective trial dose does not score 8/10 on Dose because it contains the right ingredient. It scores proportionally lower. The rubric is the enforcement mechanism.
5. Never use "clinically dosed" as a standalone claim in NC copy. The phrase must always come with a parenthetical that specifies what it means for this product, in this context.
This is stricter than anything our competitors publish. It's also more work per review. We think it's the right call — because the alternative is participating in exactly the marketing theatre we were built to cut through.
We're publishing this argument partly because we think readers deserve to know the editorial standards they're trusting, and partly because we're still not fully satisfied with our resolution to Problem 3. If you have a view on how to handle multi-ingredient clinical dosing claims, write to us. The methodology page is versioned precisely because we expect to keep updating it.
References & further reading
Disclosures: Naked Compound participates in the Amazon.in affiliate programme. Some links earn a small commission. No manufacturer provided samples or funding for this content. Full policy: conflicts-policy